Amit. Thanks
our last unprecedented of arterial in X majority population are study, ralinepag from topline background of who pulmonary PAH delivered positive treatment with dual X Phase the patients Group reminder, year a or the WHO we results As patient for therapy. hypertension with on
treatment have and ralinepag spectrum PAH the prevalent patients, received not first, believe across PAH of just and all and early provides including a prior in ralinepag ralinepag Phase our the X once-daily, ID receptor elucidate drives is oral receptor that product, study patients. and but patients, incident in or pre-clinical therapy potential program, ralinepag capacity analog. in of than development prostacyclin diagnosed a and therapy basis and designed meet and improved The exercise disease that closer prostacyclin’s newly profile a to outcomes We with because to clinical of is PAH patients has in potential other believe its of that need extended the best continuous benefits its is prostacyclin be oral program the improved potency clinical pharmacokinetics the prostacyclin to On work the any agonist that to patients. resulting best engagement
branded program, and initiated today Phase clinical that thrilled expect in to program the be conducted advanced to it program X Phase we’ve most We’re comprehensive announce PAH. X the as our ralinepag ever
this we X of point address a speed that physician We program, developed two be facilities end data. Before believe will on goals. a main program wide and advanced The Phase the range I label, rest with designed walk differentiation goals; Phase through market, program advanced experience, four is to of and X the reminder, plan as ralinepag of focus components. consisting to
each events to of time a an capacity standalone clinical is Firstly, a which exercise registrational program, for secondly to designed and program, filing.
and platform for benefits to words pathways be these to program. few believe the specific more use and payers. of and demonstrate a additional also non-registrational to ralinepag. healthcare registrational in conducting trials will provide appropriate provide robust the providers two the independent of our We speed differentiation advanced filing evidence We trials on A maximize
XXX pathway and on has anchored approximately will trial study PAH first provide care unroll compared This on recently in to to was investigating The X.XX. significant of to time of clinical a sized a therapy XX% events that’s trial. standard The placebo top patients. initiated outcomes ralinepag or trial advanced patients, prevalent level the of at
to focused agonist in incident, newly to second the patients on of intended as ERA treat PDX therapy capacity ralinepag PAH it combination or first-line and pathway in exercise of The investigate patients part is with who and diagnosed use are antagonist registrational is therapy.
advance on this QX fixed testing with walk. this will advanced initiating patients, focused trial, our recently of duration, year. separate In six-minute or in on measuring VOX in this trial diagnosed CPET be and will will distance a trials over exercise via diagnosed fixed exercise duration. focus two capacity methodologies. approximately in We’re Cardiopulmonary and six-minute again trial, uptake we over walk approaching we treatment testing oxygen In treatment a pathway separate peak we a different capacity approximately XXX XXX endurance, or capacity exercise recently peak CPET evaluate patients
advantages to deviation it time the of of endpoint, non-CPET POX of a expect six-minute in initiate qualified is decision and of types as to We number exercise trials level and provide into that next participate trial. result favoring focus a capacity trials split Each significant of The year. to primary trial a trial of endurance for in XX% enable to same CPET smaller the therefore at [indiscernible] estimation of the a a trial end-point at program X.XX. QX sites to use CPET these the on a two for as to power sized advanced is capacity broader advance primary drive standard the lower for the walk highly the number a study, this
is differentiating it two pathways described, believe the from data our the generate ralinepag to competition. important we addition In to that for I registrational compound
the prostacyclin the of trial aspect this providing use about exercise excited the adding investigating ralinepag this investigating in capacity advanced therapy clinical outcomes or and clinical will advance earlier the fall diagnosed advanced by newly details prevalent oral and is the We in program. the patients. endurance patients be PAH of more advanced incident I’m program, the foundation trials events in about program differentiation capacity of
have the more the I We the a approach because in rigorous want we PAH our read-out and and therapy as speed-to-market these broadened fixed use ralinepag with duration label to have demonstrating anticipated opportunity trials increase benefit by ahead of both the of advanced ralinepag first-line to of a taking in have is is X to program trial. to fundamentally that comprehensive best disease ralinepag outcomes previous others believe Arena and than ralinepag a emphasize programs Phase therapy. the
as benefits have look and will in Amit now, outlined timelines of clinical we the of PAH. program call studies patients [indiscernible] on October. of enabling as who a to collectively, appropriate from winning suffer elucidate that pipeline. I We’re I the remainder patients our ralinepag, you a forward confident program more to Amit? the use continue will to the we over and the back updating label advanced turn broad details range will for across to studies these active provide And We
